



San Jose BioCenter Press Release

Media Contact:
Aur lie Gaudin
The San Jose BioCenter
www.sjbiocenter.com
news@sjbiocenter.com

FOR IMMEDIATE RELEASE:

The San Jose BioCenter Announces an Important Event on Investigational New Drug Applications via Webinar as Well as Face-to-Face

FEBRUARY 9, 2010, SAN JOSE, CALIFORNIA – The San Jose BioCenter has today announced the launch of its first joint face-to-face/webinar meeting format. The March 2nd event on Investigational New Drug Applications (INDs) is primarily aimed at small companies involved in developing new chemical entities whereby the successful filing and clearance of an Investigational New Drug Application constitutes a significant milestone. Since there are many potential pitfalls to achieving a successful filing, the event is anticipated to be a sell-out for the San Jose BioCenter. Ms. Melinda Richter, CEO of the San Jose BioCenter said "This is why we are particularly pleased that this event will be open to companies that may be further afield and may not be able to attend the event at the BioCenter due to distance. They will be able to connect via a webinar link-up for the first time." She continued, "Our on-site events have been selling out very quickly, but as a non-profit aiming to support young innovative start ups and mid-stage companies, it was a real heartbreaker for us to refuse entrance to some of them just because of lack of space. This webinar is just the first step in launching a full series of events that will be accessible from anywhere in the US."

This event, produced in partnership with Liquent and Speid & Associates, Inc., will identify the pitfalls that CEOs and senior management teams need to be aware of when working on INDs. "The FDA and other regulatory authorities expect senior management teams to be aware of the drug development and regulatory process enough to protect the public's health as they develop their drugs," declared Dr. Lorna Speid, President of Speid & Associates, Inc. and panel member. "Hence the event will examine areas that CEOs and senior management teams need to give attention to."

Declares Debra Gosling, Account Executive, Regulatory & Clinical Services, Liquent Inc. "I am pleased that our topic has generated this type of interest and I look forward to moderating the first joint session at the San Jose BioCenter."

"The Ten Mistakes That Senior Management Teams Make with Investigational New Drug Applications" will begin at 12:30pm PST on March 2, 2010. The attendees registered to participate on site will be invited to have lunch and network with the speakers at the BioCenter prior to the event. Register early at http://www.sjbiocenter.com/event/ev_2010Q1-IND.html to secure your spot.

About the San Jose BioCenter

The San Jose BioCenter is a life science and cleantech incubator providing entrepreneurs with that "Big Company Advantage" through facilities, equipment, resources, contacts and expertise they need to commercialize their technology. Established in 2004 by the Redevelopment Agency of the City of San Jose and the San Jose State University Research Foundation, and managed by Prescience International, the San Jose BioCenter is the first of its kind to provide a comprehensive suite of

laboratory and business services in a plug and play facility. With a total investment of \$15M in facilities and equipment, the San Jose BioCenter has evolved into the premier destination location for emerging companies and research scientists alike. Since inception, BioCenter companies have raised more than \$1B in deals and financing, and have created more than 800 direct jobs. For more information, visit www.sjbiocenter.com.

About Liquent

Liquent, Inc., located in Horsham, PA, provides a complete spectrum of software solutions and Regulatory and Clinical outsourcing services to meet the needs of Regulatory organizations in the Life Sciences industry.

For more information, visit www.liquent.com.

About Speid & Associates, Inc.

Speid & Associates, Inc. is a privately held regulatory affairs and drug development consultancy based in San Diego, California. Speid & Associates assists life science companies move new chemical entities to the finish line expeditiously by developing effective global regulatory strategies. The Company works at all phases of drug development and has experience working with all major regulatory authorities. Speid & Associates also conducts due diligence for investors and companies. For more information, visit www.sndtm.com.

###